Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Epidemiological Observational Study on the Assessment of the Comorbidity and the Efficacy of the Treatment of Hypertensive Patients with Single Pill Combination of Lysinopril, Amlodipine and Rosuvastatin "PHENOTYPE-AG"

https://doi.org/10.20996/1819-6446-2021-08-14

Full Text:

Abstract

Aim. To study the prevalence of comorbidity affecting the choice of antihypertensive treatment, as well as the efficacy and safety of the application of a single pill combination of lysinopril, amlodipine and rosuvastatin (SPC LAR) in hypertensive patients.

Material and methods. Observational epidemiological study with the participation of 626 doctors and 13037 hypertensive patients with high cardiovascular risk and dyslipidemia treated with SPC LAR were held in 24 cities of Russia from November 2020 to March 2021. Prevalence and types of comorbidity, changes of blood pressure (BP), of total cholesterol (TC) and blood glucose levels and adverse events were studied during observation. Patients had 3 visits – initially, after 4 and 12 weeks. The obtained data was recorded by doctors through a web portal.

Results. Concominant cardiovascular diseases found in all patients (in 38.7% of cases – from 2 to 5 diseases). The most commonly diseases were coronary artery disease (43.1%), metabolic syndrome (36.6%), diabetes (25.2%), chronic heart failure (24.9%), cerebrovascular diseases (12.3%) and chronic obstructive pulmonary disease (0.5%). SPC LAR with minimal doses of components (in 41.1% of patients) or with reinforced antihypertensive or hypocholesterolemic effects, based on the experience of treatment, the patient was prescribed as starting treatment with doctors. Reducing the level of systolic and diastolic BP, as well as the level Tc, respectively, by 20.9%, 16.9% and 29.7% found during the study. Target levels of systolic BP were achieved in 97.6% of patients, diastolic BP – in 99.6%, and target levels TC ≤5 mmol/l, ≤4 mmol/l and ≤3 mmol/l were achieved, respectively, in 94.5%, 68.6% and 23.5% patients. No significant dynamics of the level of glycemia were not found. The treatment was well tolerated by patients. Side effects found in 0.53% of patients (more often there was a dry cough, feet edema and headache). Commitment to treatment was 92.7%.

Conclusion. The modern hypertension phenotype has cardiovascular atherosclerosis-associated diseases, which justifies the need to combine antihypertensive and hypolipidemic therapy. Triple SPC LAR, which effectively controlled the blood pressure and improved the violation of lipid metabolism was prescribed to patients in this observational study. The low frequency of side effects and good tolerance of treatment was accompanied by a high adherence of patients to treatment.

 

About the Authors

M. P. Savenkov
Pirogov Russian National Research Medical University
Russian Federation

Mihail P. Savenkov

eLibrary   SPIN   6315-5111

Moscow



S. N. Ivanov
Hospital for War Veterans №2
Russian Federation

Sergey N. Ivanov

Moscow



M. V. Borschevskaya
Pirogov Russian National Research Medical University
Russian Federation

Marina V. Borchshevskaya

Moscow



I. N. Okuneva
Pirogov Russian National Research Medical University
Russian Federation

Irina N. Okuneva

Moscow



S. V. Ivanova
Hospital for War Veterans №2
Russian Federation

Svetlana V. Ivanova

Moscow



A. M. Savenkova
Pirogov Russian National Research Medical University
Russian Federation

Anna M. Savenkova

Moscow



R. V. Dushkin
LLC "Agency of Artificial Intellect"
Russian Federation

Moscow



References

1. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/eurheartj/ehy339.

2. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786 (In Russ.) DOI:10.15829/1560-4071-20203-3786.

3. Myasnikov A.L. Hypertension and atherosclerosis. Moscow: Medicine; 1965 (In Russ.)

4. Zadionchenko VS, Shekhyan GG, Timofeeva NYu, Yalymov AA. Results of clinical trials of the drug Equator® in the treatment of arterial hypertension. Russian Medical Journal. 2012;20(11):554-58 (In Russ.)

5. Galeeva ZM, Galyavich AS. Fixed combination of lisinopril with amlodipine in combination with rosuvastatin in patients with hypertension and coronary heart disease. Ter Arkhiv. 2014;86(9):71-6 (In Russ.)

6. Karpov YuA. TRIUMVIRATE study: reducing the risk of cardiovascular complications in patients with arterial hypertension using a three-component combination of antihypertensive and lipid-lowering drugs. Kardiologiia. 2015;55(9):10-5 (In Russ.) DOI:10.18565/cardio.2015.9.10-15.

7. Kónyi A, Sárszegi Z, Hild G, Gaszner B. Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients. J Comp Eff Res. 2016;5(4):355-64. DOI:10.2217/cer-2016-0003.

8. Blankova ZN, Aslanyan NS. The effect of combination therapy on the state of the vascular wall in patients with high cardiovascular risk. Systemic Hypertension. 2017;14(2):51-5 (In Russ.) DOI:10.26442/2075-082X_14.2.51-55

9. Savenkov MP, Ivanov SN, Mikhailusova MP, et al. Fixed etiopathogenetic combination of drugs for the treatment of arterial hypertension. Meditsinskiy Sovet. 2017;(11):12-6 (In Russ.). DOI:10.21518/2079-701X-2017-12-16.

10. Nedogoda SV, Chumachek EV, Ledyaeva AA, et al. Optimal organoprotection, control of blood pressure and metabolic disorder with the fixed combination of lisinopril, amlodipine and rosuvastatin in systemic hypertension. Russian Journal of Cardiology. 2018;(4):49-55 (In Russ.). DOI:10.15829/1560-4071-2018-4-49-55.

11. Savenkov MP, Kirichenko AV, Borshchevskaya MV, et al. Circadian and seasonal efficacy of lisinopril in the treatment of arterial hypertension. Consilium Medicum. 2013;15(5):17-20 (In Russ.)

12. Chazova IE, Blinova NV, Nevzorova VA, et al. Russian Medical Society for Arterial Hypertension Expert Consensus: Hypertension and COVID-19. Systemic Hypertension. 2020;17(3):35-41 (In Russ.) DOI:10.26442/2075082X.2020.3.200362.


For citation:


Savenkov M.P., Ivanov S.N., Borschevskaya M.V., Okuneva I.N., Ivanova S.V., Savenkova A.M., Dushkin R.V. Epidemiological Observational Study on the Assessment of the Comorbidity and the Efficacy of the Treatment of Hypertensive Patients with Single Pill Combination of Lysinopril, Amlodipine and Rosuvastatin "PHENOTYPE-AG". Rational Pharmacotherapy in Cardiology. 2021;17(4):528-536. (In Russ.) https://doi.org/10.20996/1819-6446-2021-08-14

Views: 299


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)